# Study of IBI3016 in People With Mild or Moderate Hypertension Patients

> **NCT07556796** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** IBI3016
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07556796
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2027-10-16
- **Final completion:** 2027-10-16
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07556796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07556796, "Study of IBI3016 in People With Mild or Moderate Hypertension Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07556796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*